

Original Investigation

Meta-analysis of Genome-wide Association Studies for Neuroticism, and the Polygenic Association With Major Depressive Disorder

Genetics of Personality Consortium

IMPORTANCE Neuroticism is a pervasive risk factor for psychiatric conditions. It genetically overlaps with major depressive disorder (MDD) and is therefore an important phenotype for psychiatric genetics. The Genetics of Personality Consortium has created a resource for genome-wide association analyses of personality traits in more than 63 000 participants (including MDD cases).

OBJECTIVES To identify genetic variants associated with neuroticism by performing a meta-analysis of genome-wide association results based on 1000 Genomes imputation; to evaluate whether common genetic variants as assessed by single-nucleotide polymorphisms (SNPs) explain variation in neuroticism by estimating SNP-based heritability; and to examine whether SNPs that predict neuroticism also predict MDD.

DESIGN, SETTING, AND PARTICIPANTS Genome-wide association meta-analysis of 30 cohorts with genome-wide genotype, personality, and MDD data from the Genetics of Personality Consortium. The study included 63 661 participants from 29 discovery cohorts and 9786 participants from a replication cohort. Participants came from Europe, the United States, or Australia. Analyses were conducted between 2012 and 2014.

MAIN OUTCOMES AND MEASURES Neuroticism scores harmonized across all 29 discovery cohorts by item response theory analysis, and clinical MDD case-control status in 2 of the cohorts.

RESULTS A genome-wide significant SNP was found on 3p14 in *MAG11* (rs35855737; $P = 9.26 \times 10^{-9}$ in the discovery meta-analysis). This association was not replicated ($P = .32$), but the SNP was still genome-wide significant in the meta-analysis of all 30 cohorts ($P = 2.38 \times 10^{-8}$). Common genetic variants explain 15% of the variance in neuroticism. Polygenic scores based on the meta-analysis of neuroticism in 27 cohorts significantly predicted neuroticism ($1.09 \times 10^{-12} < P < .05$) and MDD ($4.02 \times 10^{-9} < P < .05$) in the 2 other cohorts.

CONCLUSIONS AND RELEVANCE This study identifies a novel locus for neuroticism. The variant is located in a known gene that has been associated with bipolar disorder and schizophrenia in previous studies. In addition, the study shows that neuroticism is influenced by many genetic variants of small effect that are either common or tagged by common variants. These genetic variants also influence MDD. Future studies should confirm the role of the *MAG11* locus for neuroticism and further investigate the association of *MAG11* and the polygenic association to a range of other psychiatric disorders that are phenotypically correlated with neuroticism.

JAMA Psychiatry. doi:10.1001/jamapsychiatry.2015.0554
Published online May 20, 2015.

+ Author Audio Interview at jamapsychiatry.com

+ Supplemental content at jamapsychiatry.com

The Authors/Members of the Genetics of Personality Consortium are listed at the end of this article.

Corresponding Author: Marleen H. M. de Moor, PhD, Department of Clinical Child and Family Studies, VU University Amsterdam, Van der Boechorststraat 1, 1081 BT Amsterdam, the Netherlands (m.h.m.de.moor@vu.nl).

Dimensions of personality have been linked with the liability to have psychiatric illness.¹ Perhaps the strongest link between personality and psychiatric illness is the association of neuroticism with major depressive disorder (MDD).²⁻⁵ Neuroticism is also associated with other psychiatric disorders that entail emotional dysregulation, including personality, substance use, and anxiety disorders.^{2,6-8} Furthermore, neuroticism is associated with neurological diseases such as migraine and Alzheimer disease.^{9,10} Hence, neuroticism is a psychological risk factor of profound public health significance.¹¹

Neuroticism refers to the tendency to experience diverse and relatively more intense negative emotions. Neuroticism and similar traits such as harm avoidance and negative emotionality share an affective underpinning¹² and are found in all main theories of personality.¹³⁻²⁴ Twin studies of neuroticism, harm avoidance, or negative emotionality generally find that between 40% and 60% of the trait variance is explained by genomic variation,^{3,25-28} and it has been found that there are no large age-by-genotype or sex-by-genotype effects, modest assortative mating, and large genetic and phenotypic stability across the life span.²⁸⁻³¹ These findings and the fact that neuroticism is strongly related to MDD^{7,32-35} make neuroticism an important phenotype for psychiatric genetic studies.

Genome-wide association (GWA) studies require large sample sizes to have sufficient statistical power, which is often achieved by aggregating results in multiple cohorts in a meta-analysis. However, this requires a measurement scale that is comparable across cohorts. We recently showed for neuroticism and extraversion how different personality instruments could be linked through item response theory analysis to assess the same underlying constructs.³⁶ Personality item data were harmonized in more than 160 000 participants from the Genetics of Personality Consortium. A meta-analysis of data from more than 29 000 twin pairs from 6 of the participating cohorts showed that the heritability of the harmonized neuroticism scores was 48%.³⁶ This estimate was based on twin correlations that ranged between 0.39 and 0.53 for monozygotic twin pairs and between 0.11 and 0.26 for dizygotic twin pairs across cohorts and sexes. The opposite-sex twin correlations were not significantly lower than the same-sex dizygotic twin correlations, illustrating that the same genetic factors influence neuroticism in men and women.

Gene-finding studies for MDD and neuroticism-like personality traits have had limited success to date. There have been 2 meta-analytic GWA studies for personality traits, including neuroticism and harm avoidance. The sample sizes were small by current standards ($N = 11\,590$ in the study by Service et al³⁷ and $N = 17\,375$ in the study by de Moor et al³⁸) and single-nucleotide polymorphisms (SNPs) were imputed using HAPMAP as a reference. The largest GWA³⁹⁻⁴¹ studies for MDD are those from the Psychiatric Genomics Consortium, with 9240 MDD cases and 9519 controls in the discovery phase of the study and 6783 MDD cases and 50 695 controls in the replication phase, and imputation based on HAPMAP. These studies did not detect genome-wide significant SNPs.⁴²

To assess whether gene-finding efforts are likely to have success, techniques have been developed that test whether

common variants tagged by genome-wide SNP arrays contribute to variation in the phenotype.⁴³ Two such studies for neuroticism found effects of common SNPs, explaining about 6% of the phenotypic variance, and another study for MDD found that common SNPs explain 28% to 32% of the phenotypic variance.⁴⁴⁻⁴⁶ In young children, genome-wide SNPs explained 13% to 43% of the variance in internalizing problems.⁴⁷

Herein, we report results of the largest GWA study for neuroticism so far, to our knowledge, conducted in 63 661 participants from 29 cohorts. A replication cohort of 9786 participants was also included. Imputation was performed against the 1000 Genomes reference panel. The main aim of the study was to identify genetic variants for neuroticism by performing a meta-analysis of GWA results. Additional aims were to estimate SNP-based heritability in 2 of the largest cohorts to establish that the sets of SNPs contain information to detect genetic variants and to test whether these variants predict MDD status in a large cohort of clinically assessed MDD cases and screened controls.

Methods

Cohorts


The meta-analysis included 29 discovery cohorts, with 21 cohorts from Europe, 6 from the United States, and 2 from Australia. The analyses were conducted between 2012 and 2014. All participants were of European descent. The total sample size was 63 661 for the GWA meta-analysis. The Generation Scotland: Scottish Family Health Study cohort ($n = 9786$) was included for replication of GWA top results. For more information on each cohort, see eAppendix 1 and eTable 1 in the Supplement. Approval by local institutional review boards was obtained in all studies and informed consent was obtained from all participants.

Phenotyping

After harmonizing all item data on neuroticism from multiple instruments, comparable neuroticism scores were obtained for all cohorts.³⁶ These scores were estimated for all participants after conducting item response theory analysis on the available item data for neuroticism from the NEO Personality Inventory, Eysenck Personality Questionnaire, and International Personality Item Pool inventory, all item data for harm avoidance from Cloninger's Tridimensional Personality Questionnaire, and all item data for negative emotionality from the Multidimensional Personality Questionnaire (eAppendix 1 in the Supplement). For the Generation Scotland cohort, phenotypes were summed scores on the neuroticism scale of the Eysenck Personality Questionnaire Revised Short Form.

Genotyping and Imputation

An overview of SNP genotyping, quality control, and imputation is given in eTable 2 in the Supplement. Quality control of genotype data was performed in each study independently, using comparable but study-specific criteria. Basic quality control steps included checks for European ancestry, sex incon-

Figure 1. Region Plot for Genome-wide Significant Single-Nucleotide Polymorphism (SNP) rs35855737 in *MAG1* on Chromosome 3 for Neuroticism

Mb indicates megabase.

sistencies, mendelian errors, and high genome-wide homozygosity. Checks for relatedness were carried out in those samples that aimed to include unrelated individuals only. Genotype data were further checked based on Hardy-Weinberg equilibrium, minor allele frequencies (MAFs), SNP, and sample call rates. Genotype data were imputed using the 1000 Genomes phase 1 version 3 (build 37, hg19) reference panel with standard software packages such as IMPUTE, MACH, or Minimac (eTable 2 in the Supplement).

Statistical Analysis

GWA Analyses in Each Cohort

The GWA analyses were conducted in each cohort using linear regression (additive model, with sex and age as covariates) with the aim to identify single common genetic variants that influence neuroticism in both men and women of different ages. Depending on the characteristics of the cohort, additional covariates such as principal components were added. Different software packages were used to run the association analysis (eTable 2 in the Supplement). Uncertainty of the imputed genotypes was taken into account. In those cohorts that included related individuals, the dependency among participants was accounted for. Locations of SNPs are reported on build 37 (hg19).

Meta-analysis of GWA Results Across Cohorts

A meta-analysis of the GWA results of the discovery cohorts was conducted using the weighted inverse variance method

in METAL (<http://csg.sph.umich.edu/abecasis/Metal/>). This is a fixed-effects model in which effect sizes (β) are weighted by the inverse of their variance and then summed over cohorts. This model is appropriate if phenotypes are on a similar scale, which was the case for the harmonized neuroticism scores. Poorly imputed SNPs ($r^2 < 0.30$ or $\text{proper_info} < 0.40$) and SNPs with low MAF ($\text{MAF} < \sqrt{[5/n]}$, which corresponds to fewer than 5 estimated individuals in the least frequent genotype group, under the assumption of Hardy-Weinberg equilibrium) were excluded, resulting in a total number of 1.1 million to 6.6 million SNPs across cohorts. The number of unique SNPs available for meta-analysis was 7 480 565. For 530 951 SNPs, association results were available in 1 cohort only and were discarded, leading to a final 6 949 614 SNPs for which results are reported. Genomic control inflation factors (λ) and Manhattan and quantile-quantile plots per cohort are provided in eTable 3, eFigure 1, and eFigure 2 in the Supplement. The SNPs with $P = 5 \times 10^{-8}$ or smaller were considered genome-wide significant. In the Generation Scotland cohort, all SNPs with $P < 1 \times 10^{-5}$ were tested for replication. For these SNPs, a meta-analysis of all 30 cohorts was conducted. Because sum scores were available for neuroticism in the Generation Scotland cohort, this meta-analysis was based on combining P values, taking into account the direction of effect and weighting by sample size, rather than combining effect sizes.

Variance Explained by Common SNPs

In 2 large cohorts included in the meta-analysis, the Netherlands Twin Register (NTR; n = 3599 unrelated individuals) cohort and the QIMR Berghofer Medical Research Institute (QIMR; n = 3369) adult cohort, genomic-relatedness-matrix restricted maximum likelihood analysis in the Genome-wide Complex Trait Analysis (GCTA) software was applied to estimate the proportion of variance in neuroticism that can be explained by common SNPs.^{43,48} The GCTA analysis was based on best-guess genotypes obtained in PLINK using a threshold of a maximum genotype probability > 0.70, and additionally filtering on $r^2 > 0.80$. Next, in estimating the genetic relationship matrix in the GCTA software, SNPs with MAF < 0.05 were excluded. The additive genetic relationship matrix for all individuals in the data sets estimated based on SNPs was used to estimate the proportion of phenotypic variance due to additive genetic variance. Sex, age, and population-specific principal components were included as covariates.

Polygenic Risk Score Analysis


Polygenic risk score (PGS) analyses were conducted to test the predictive power of the meta-analysis results for neuroticism itself and for MDD. The PGSs were computed in the NTR cohort and the Netherlands Study of Depression and Anxiety (NESDA) cohort⁴⁹ and were based on the meta-analysis results excluding the NTR and NESDA cohorts, further referred to as the PGS discovery set. The PGSs were calculated for all individuals of the NTR and NESDA target set by taking a set of most significant SNPs from the analysis in the PGS discovery set, multiplying the individual's genotypic score (0, 1, or 2 for genotyped SNPs, or any value between 0-2 for imputed SNPs) by the effect size of a particular SNP (unstandardized regression coefficient based on the meta-analysis), and summing this over SNPs. The PGSs were calculated for 6 P value thresholds ($P < 1 \times 10^{-5}$, $P < 1 \times 10^{-4}$, $P < 1 \times 10^{-3}$, $P < .01$, $P < .05$ and $P < .50$). Next, linear regression was conducted to predict neuroticism from the PGSs in 8648 NTR participants. Logistic regression was conducted to predict MDD status in 1859 unrelated MDD cases and 2391 unrelated controls from the NTR and NESDA cohorts. The MDD case-control status was defined as a lifetime *DSM-IV* diagnosis using the Composite International Diagnostic Interview. Age, sex, and 9 principal components were included as covariates. eAppendix 1 in the Supplement includes more details on selection of participants in these cohorts and analysis.

Results

Meta-analysis of GWA Results for Neuroticism

Meta-analysis of GWA results across the 29 cohorts revealed 1 genome-wide significant SNP (rs35855737; $P = 9.26 \times 10^{-9}$). The SNP is located on 3p14 in an intron of *MAG11* (Figure 1). The pooled regression effect was -0.04 with the minor allele C coded as the effect allele (Figure 2). Imputation quality was very high (r^2 or proper_info > 0.94) in all cohorts, except in the Erasmus Rucphen Family (ERF) cohort ($r^2 = 0.63$). The MAF of the SNP ranged from 0.13 to 0.22 across cohorts with imputation


Figure 2. Forest Plot for Genome-wide Significant Single-Nucleotide Polymorphism rs35855737 in *MAG11* on Chromosome 3 for Neuroticism



Order of cohorts is by standard error. ALSPAC indicates Avon Longitudinal Study of Parents and Their Children; BLSA, Baltimore Longitudinal Study of Aging; COGA, Collaborative Study on the Genetics of Alcoholism; COGEND, Collaborative Genetic Study of Nicotine Dependence; EGCUT, Estonian Genome Project of University of Tartu; ERF, Erasmus Rucphen Family; FTC EPI, Finnish Twin Cohort sample with Eysenck Personality Inventory data; FTC NEO, Finnish Twin Cohort sample with NEO Personality Inventory data; HBCS, Helsinki Birth Cohort Study; LBC1921, Lothian Birth Cohort 1921; LBC1936, Lothian Birth Cohort 1936; MCTFR, Minnesota Center for Twin and Family Research; MGS, Molecular Genetics of Schizophrenia Control Sample; NBS, Nijmegen Biomedical Study; NESDA, Netherlands Study of Depression and Anxiety; NTR, Netherlands Twin Register; ORCADES, Orkney Complex Disease Study; QIMR adolescents, QIMR Berghofer Medical Research Institute Study in Adolescents; QIMR adults, QIMR Berghofer Medical Research Institute Study in Adults; SHIP, Study of Health in Pomerania; STR, Swedish Twin Registry; and YFS, Young Finns Study.


quality greater than 0.94 and showed a mean (SD) of 0.18 (0.02), which corresponds to the MAF for this SNP in the 1000 Genomes reference set. The MAF in the ERF cohort was 0.07. Eleven other SNPs in *MAG11* showed suggestive genome-wide significance ($P < 1 \times 10^{-5}$); all SNPs were intronic; 1 SNP was in very high linkage disequilibrium with rs35855737 (rs1404544; $r^2 > 0.80$; $P = 8.59 \times 10^{-6}$); and 3 SNPs were in high linkage disequilibrium with rs35855737 (rs1524970, rs1880522, and rs6799284; $r^2 > 0.60$; $3.64 \times 10^{-6} < P < 8.54 \times 10^{-7}$). The

Figure 3. Manhattan Plot for Meta-analysis Results for Neuroticism in 29 Discovery Cohorts



Blue line indicates the threshold of suggestive genome-wide significance $P < 1 \times 10^{-5}$ (or the log thereof); red line, threshold of genome-wide significance $P < 5.0 \times 10^{-8}$ (or the log thereof).

Figure 4. Quantile-Quantile Plots for Meta-analysis Results for Neuroticism in 29 Discovery Cohorts




Black dots indicate the relationship between the observed $-\log_{10}$ of the P values across all tested single-nucleotide polymorphisms (y-axis) and the expected $-\log_{10}$ of the P values across all tested single-nucleotide polymorphisms under the null hypothesis of no single-nucleotide polymorphism associations (x-axis); red line, the relationship between the expected $-\log_{10}$ of the P values across all tested single-nucleotide polymorphisms (y-axis) and the expected $-\log_{10}$ of the P values across all tested single-nucleotide polymorphisms under the null hypothesis of no single-nucleotide polymorphism associations (x-axis); and shaded area, 95% CI.

Manhattan and quantile-quantile plots are shown in **Figure 3** and **Figure 4**. A list with all 127 suggestively genome-wide significant SNPs is provided in eTable 4 in the Supplement (full results of the meta-analysis can be downloaded from <http://www.tweelingenregister.org/GPC>).

Results of the follow-up analysis for all SNPs with $P < 1 \times 10^{-5}$ in the Generation Scotland cohort are displayed in eTable 4 in the Supplement. The SNP rs35855737 is not significantly associated with neuroticism in the Generation Scotland cohort, but the direction of the effect is the same ($\beta = -0.02$ for effect allele C; $P = .32$). A meta-analysis of the results from all 30 cohorts shows that rs35855737 remains genome-wide significant ($\beta = -0.04$; $P = 2.38 \times 10^{-8}$).

Figure 5. Results of Polygenic Risk Score Analyses Predicting Major Depressive Disorder (MDD) and Neuroticism Based on Neuroticism Polygenic Risk Scores



Prediction of neuroticism in the Netherlands Twin Register cohort and MDD in the combined Netherlands Twin Register and Netherlands Study of Depression and Anxiety cohorts are based on neuroticism polygenic risk scores from the meta-analysis results in which the Netherlands Twin Register and Netherlands Study of Depression and Anxiety cohorts were omitted. The P value thresholds were used to calculate the polygenic risk scores. Percentage of variance refers to R^2 in the linear regression of neuroticism on the polygenic risk scores and to the Nagelkerke R^2 in the logistic regression of MDD on the polygenic risk scores.

^a Significant prediction ($P < .05$).

^b Significant prediction ($P < .001$).

Variance in Neuroticism Explained by Common SNPs

In the NTR cohort, 14.7% of the variance in neuroticism was explained by all SNPs ($P = .02$; 95% CI, 0.002-0.29). In the QIMR cohort, 15.7% of the variance was explained by SNPs ($P = .18$; 95% CI, 0-0.47).

Polygenic Risk Score Analysis for Neuroticism and MDD

The results of the polygenic risk score analyses are presented in **Figure 5**. In the NTR cohort, polygenic risk scores are significantly ($P < .05$) associated with neuroticism when polygenic scores are based on SNP sets with thresholds of

$P = 1 \times 10^{-3}$ and lower. The most significant result was found for the SNP set with a threshold $P = .50$, with an explained variance of 0.66% and $P = 1.09 \times 10^{-12}$ in the linear regression analysis. In the combined NTR and NESDA cohorts, polygenic risk scores are significantly ($P < .05$) associated with MDD for SNP sets with thresholds of $P = .01$ and $P = .05$, with higher neuroticism predicting larger risk for MDD. The most significant result was found for the SNP set with a threshold of $P = .05$, with an explained variance of 1.05% and $P = 4.02 \times 10^{-9}$ in the logistic regression analysis.

Discussion

The meta-analysis of GWA results for neuroticism showed a genome-wide significant SNP on 3p14 in an intron of *MAG1I*. This gene is expressed in neuronal tissue, in particular the hippocampus, and is found at the synaptic plasma membrane.⁵⁰ Also, *MAG1I* acts as a scaffolding protein in the neurite growth factor receptor-mediated signaling pathway.⁵¹ Interestingly, *MAG1I* has previously been implicated in bipolar disorder, schizophrenia, and episodicity in MDD,⁵²⁻⁵⁴ disorders that in part share their genetic etiology.⁵⁵ A genome-wide linkage scan for early-onset bipolar disorder type 1 revealed genome-wide significant linkage in the 3p14 region where *MAG1I* is located.⁵⁴ A study of copy number variants found deletions and duplications in *MAG1I* to be associated with bipolar disorder and schizophrenia.⁵² Further, a suggestive association ($P = 5.1 \times 10^{-7}$) of an SNP in *MAG1I* with episodicity in MDD was found in a GWA study. Episodicity is a feature of MDD that shows increased risk to shifting to bipolar disorder.⁵³

The SNP-based genetic similarity across individuals accounted for approximately 15% of the variance in neuroticism. This estimate is larger than those in earlier reports, of about 6%.^{44,46} Heritability estimates from twin studies are usually larger and range between 40% and 55%.³⁶

Polygenic risk scores based on the GWA meta-analysis significantly predicted MDD status in a large independent target set consisting of MDD cases and screened controls. The polygenic scores for neuroticism reassuringly also predicted neuroticism in controls for MDD of this same independent set. Neuroticism and MDD were explained about equally well by neuroticism polygenic scores (up to 1.05% explained variance). These findings are consistent with previous reports that studied the prediction of MDD and bipolar disorder based on polygenic scores derived from Big Five neuroticism GWA results.^{56,57}

This study demonstrates that increasing the number of participants and SNPs in a meta-analysis was successful in identifying a novel locus for neuroticism. As expected, the effect size of the identified SNP is very small (pooled regression coefficient of -0.04 for the harmonized score with a variance of approximately 1). Together with our findings of an SNP-based heritability of approximately 15% and an increase in explained variance in the polygenic risk score analysis when polygenic scores are based on larger sets of SNPs, this suggests that neuroticism is highly polygenic.

Our results further indicate that the heritability of neuroticism likely consists not only of common SNPs with small effects. Rare variants, repeat polymorphisms, and indels may also influence neuroticism, possibly in gene-by-gene interactions (epistasis). As a consequence, to further our understanding of the genetic and molecular basis of neuroticism (and associated psychiatric disorders), different routes need to be taken in future studies. One route would be to increase the number of participants and SNPs to further identify common variants. This route was shown to be very successful for schizophrenia.⁵⁸ Also, the study of variants other than common SNPs should be pursued. Alternative routes could include pathway analyses and genetic studies that are informed by results from the animal literature on basic emotions such as fear, sadness, and anger.⁵⁹⁻⁶²

This study more than tripled the sample size compared with the previously published meta-analysis on personality,³⁸ providing a substantial increase in power to detect variants. The power to detect variants that explain 0.23% of the variance (corresponding to the effect size for the most significant SNP in the previous meta-analysis³⁸) increased from 84% to 100%. In addition, with a sample size of 63 661 individuals there is 80% power to detect variants that explain at least 0.063% of the variance in neuroticism, compared with 1.6% power given the 17 375 participants who were included in the previous meta-analysis.³⁸ The large increase in sample size was possible because an item response theory approach enabled harmonization of personality data obtained from different personality questionnaires, which may serve as an example for gene-finding studies for other psychological, cognitive, and psychiatric traits where harmonization is required to increase sample size (eg, symptoms of depression or attention-deficit/hyperactivity disorder measured by different questionnaires).

Conclusions

The results for neuroticism were predictive for MDD. Future analyses may focus on whether the *MAG1I* locus and polygenic variance for neuroticism are also associated with psychiatric disorders that are phenotypically associated with neuroticism, such as borderline personality disorder, bipolar disorder, schizophrenia, attention-deficit/hyperactivity disorder, and substance use disorders. This could be achieved by combining data from the Genetics of Personality Consortium with those available within the Psychiatric Genomics Consortium⁶³ and the Social Science Genetic Association Consortium.⁶⁴ Novel methods will be needed to test whether neuroticism represents a causal risk factor for MDD and other disorders, whether reverse causality is also present, or whether the genetic association between neuroticism and psychiatric disorders reflects an underlying common liability.^{55,65-67} It is expected that such studies will increase our understanding of the role that emotional instability plays in the occurrence and course of psychiatric disorders and other important health outcomes.

ARTICLE INFORMATION

Published Online: May 20, 2015.

doi:10.1001/jamapsychiatry.2015.0554.

Genetics of Personality Consortium: Marleen H. M. de Moor, PhD; Stéphanie M. van den Berg, PhD; Karin J. H. Verweij, PhD; Robert F. Krueger, PhD; Michelle Luciano, PhD; Alejandro Arias Vasquez, PhD; Lindsay K. Matteson, PhD; Jaime Derringer, PhD; Tõnu Esko, PhD; Najaf Amin, PhD; Scott D. Gordon, PhD; Narelle K. Hansell, PhD; Amy B. Hart, PhD; Ilkka Seppälä, PhD; Jennifer E. Huffman, PhD; Bettina Konte, MSc; Jari Lahti, PhD; Minyoung Lee, PhD; Mike Miller, PhD; Teresa Nutile, PhD; Toshiko Tanaka, PhD; Alexander Teumer, PhD; Alexander Viktorin, PhD; Juho Wedenoja, MD, PhD; Goncalo R. Abecasis, PhD; Daniel E. Adkins, PhD; Arpana Agrawal, PhD; Jüri Allik, PhD; Katja Appel, PhD; Timothy B. Bigdeli, PhD; Fabio Busonero, PhD; Harry Campbell, PhD; Paul T. Costa, PhD; George Davey Smith, PhD; Gail Davies, PhD; Harriet de Wit, PhD; Jun Ding, PhD; Barbara E. Engelhardt, PhD; Johan G. Eriksson, PhD; Iryna O. Fedko, MSc; Luigi Ferrucci, PhD; Barbara Franke, PhD; Ina Giegling, PhD; Richard Gruzca, PhD; Annette M. Hartmann, PhD; Andrew C. Heath, PhD; Kati Heinonen, PhD; Anjali K. Henders, PhD; Georg Homuth, PhD; Jouke-Jan Hottenga, PhD; William G. Iacono, PhD; Joost Janzing, PhD; Markus Jokela, PhD; Robert Karlsson, PhD; John P. Kemp, PhD; Matthew G. Kirkpatrick, PhD; Antti Latvala, PhD; Terho Lehtimäki, PhD; David C. Liewald, BSc; Pamela A. F. Madden, PhD; Chiara Magri, PhD; Patrik K. E. Magnusson, PhD; Jonathan Marten, MSc; Andrea Maschio, PhD; Sarah E. Medland, PhD; Evelin Mihailov, PhD; Yuri Milaneschi, PhD; Grant W. Montgomery, PhD; Matthias Nauck, PhD; Klaasjan G. Ouwens, MSc; Aarno Palotie, PhD; Erik Pettersson, PhD; Ozren Polasek, PhD; Yong Qian, MSc; Laura Pulkki-Råback, PhD; Olli T. Raitakari, PhD; Anu Realo, PhD; Richard J. Rose, PhD; Daniela Ruggiero, PhD; Carsten O. Schmidt, PhD; Wendy S. Slutske, PhD; Rossella Sorice, PhD; John M. Starr, PhD; Beate St Pourcain, PhD; Angelina R. Sutin, PhD; Nicholas J. Timpson, PhD; Holly Trochet, PhD; Sita Vermeulen, PhD; Eero Vuoksimaa, PhD; Elisabeth Widen, PhD; Jasper Wouda, MSc; Margaret J. Wright, PhD; Lina Zgaga, PhD; David Porteous, PhD; Alessandra Minelli, PhD; Abraham A. Palmer, PhD; Dan Rujescu, PhD; Marina Ciullo, PhD; Caroline Hayward, PhD; Igor Rudan, PhD; Andres Metspalu, PhD; Jaakko Kaprio, MD, PhD; Ian J. Deary, PhD; Katri Räikkönen, PhD; James F. Wilson, PhD; Liisa Keltikangas-Järvinen, PhD; Laura J. Bierut, PhD; John M. Hettema, PhD; Hans J. Grabe, PhD; Cornelia M. van Duijn, PhD; David M. Evans, PhD; David Schlessinger, PhD; Nancy L. Pedersen, PhD; Antonio Terracciano, PhD; Matt McGue, PhD; Brenda W. J. H. Penninx, PhD; Nicholas G. Martin, PhD; Dorret I. Boomsma, PhD.

Affiliations of Genetics of Personality

Consortium: Department of Clinical Child and Family Studies, VU University Amsterdam, Amsterdam, the Netherlands (de Moor); Department of Methods, VU University Amsterdam, Amsterdam, the Netherlands (de Moor); Department of Biological Psychology, VU University Amsterdam, Amsterdam, the Netherlands (de Moor, Fedko, Hottenga, Ouwens, Wouda, Boomsma); Department of Research Methodology, Measurement, and Data Analysis, University of Twente, Enschede, the Netherlands (van den Berg, Wouda); Department of

Developmental Psychology, EMGO Institute for Health and Care Research, VU University Amsterdam, Amsterdam, the Netherlands (Verweij); QIMR Berghofer Medical Research Institute, Herston, Brisbane, Australia (Verweij, Gordon, Hansell, Henders, Medland, Montgomery, Wright, Martin); Department of Psychology, University of Minnesota, Minneapolis (Krueger, Matteson, Miller, Iacono, McGue); Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, Scotland (Luciano, Davies, Liewald, Starr, Deary); Department of Psychology, University of Edinburgh, Edinburgh, Scotland (Luciano, Davies, Liewald, Deary); Department of Cognitive Neuroscience, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands (Arias Vasquez); Donders Institute for Cognitive Neuroscience, Radboud University Nijmegen, Nijmegen, the Netherlands (Arias Vasquez, Franke); Department of Psychiatry, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands (Arias Vasquez, Franke, Janzing); Department of Human Genetics, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands (Arias Vasquez, Franke, Vermeulen); Department of Psychology, University of Illinois at Urbana-Champaign, Champaign (Derringer); Estonian Genome Center, University of Tartu, Tartu, Estonia (Esko, Mihailov, Metspalu); Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands (Amin, van Duijn); Department of Human Genetics, University of Chicago, Chicago, Illinois (Hart, Palmer); Department of Clinical Chemistry, Fimlab Laboratories and School of Medicine, University of Tampere, Tampere, Finland (Seppälä, Lehtimäki); Medical Research Council Human Genetics, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, Scotland (Huffman, Marten, Trochet, Hayward); Department of Psychiatry, University of Halle, Halle, Germany (Konte, Giegling, Hartmann, Rujescu); Folkhälsan Research Center, Helsinki, Finland (Lahti, Eriksson, Terracciano); Institute of Behavioural Sciences, University of Helsinki, Helsinki, Finland (Lahti, Heinonen, Jokela, Pulkki-Råback, Räikkönen, Keltikangas-Järvinen); Department of Psychiatry, Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond (Lee, Bigdeli, Hettema); Institute of Genetics and Biophysics "A. Buzzati-Traverso," National Research Council of Italy, Naples, Italy (Nutile, Ruggiero, Sorice, Ciullo, Pedersen); National Institute on Aging, National Institutes of Health, Baltimore, Maryland (Tanaka, Ding, Ferrucci, Qian, Sutin, Schlessinger); Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany (Teumer, Schmidt); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Viktorin, Karlsson, Magnusson, Pettersson); Department of Public Health, University of Helsinki, Helsinki, Finland (Wedenoja, Latvala, Vuoksimaa, Kaprio); Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor (Abecasis); Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond (Adkins); Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri (Agrawal, Gruzca,

Heath, Madden, Bierut); Department of Psychology, University of Tartu, Tartu, Estonia (Allik, Realo); Estonian Academy of Sciences, Tallinn, Estonia (Allik, Metspalu); Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany (Appel, Grabe); Istituto di Ricerca Genetica e Biomedica, National Research Council of Italy, Monserrato, Italy (Busonero, Maschio); Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, Scotland (Campbell, Zgaga, Rudan, Wilson); Behavioral Medicine Research Center, Duke University School of Medicine, Durham, North Carolina (Costa); Medical Research Council Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Bristol, England (Davey Smith, Kemp, St Pourcain, Timpson, Evans); Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, Illinois (de Wit, Kirkpatrick, Palmer); Department of Computer Science, Princeton University, Princeton, New Jersey (Engelhardt); Department of General Practice and Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland (Eriksson); Vasa Central Hospital, Vasa, Finland (Eriksson); National Institute for Health and Welfare, Helsinki, Finland (Eriksson, Latvala, Kaprio); Interfaculty Institute for Genetics and Functional Genomics, University of Greifswald, Greifswald, Germany (Homuth); University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia (Kemp, Evans); Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy (Magri, Minelli); Department of Biotechnology, University of Tartu, Tartu, Estonia (Mihailov); Department of Psychiatry, EMGO+ Institute, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands (Milaneschi, Penninx); Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany (Nauck); Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, England (Palotie); Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland (Palotie, Widen, Kaprio); Department of Public Health, Faculty of Medicine, University of Split, Split, Croatia (Polasek); Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland (Raitakari); Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland (Raitakari); Department of Psychological and Brain Sciences, Indiana University, Bloomington (Rose); Department of Psychological Sciences and Missouri Alcoholism Research Center, University of Missouri, Columbia (Slutske); Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, Scotland (Starr); School of Oral and Dental Sciences, University of Bristol, Bristol, England (St Pourcain); School of Experimental Psychology, University of Bristol, Bristol, England (St Pourcain); College of Medicine, Florida State University, Tallahassee (Sutin, Terracciano); Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands (Vermeulen); Department of Public Health and Primary Care, Trinity College Dublin, Dublin, Ireland (Zgaga); Medical Genetics Section, University of Edinburgh, Centre for Genomic and

Experimental Medicine, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, Scotland (Porteous); Generation Scotland, University of Edinburgh, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, Scotland (Hayward); Department of Psychiatry and Psychotherapy, HELIOS Hospital Stralsund, Stralsund, Germany (Grabe); Institute of Public Health, University of Southern Denmark, Odense, Denmark (McGue).

Submitted for Publication: September 2, 2014; final revision received March 5, 2015; accepted March 7, 2015.

Author Contributions: Drs de Moor and van den Berg had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs de Moor and van den Berg share first authorship.

Study concept and design: de Moor, van den Berg, Abecasis, Davey Smith, Franke, Lehtimäki, Magnusson, Maschio, PulKKi-Råback, Raitakari, Starr, Zgaga, Rudan, Deary, Råikkönen, Grabe, van Duijn, Terracciano, McGue, Boomsma.

Acquisition, analysis, or interpretation of data: de Moor, van den Berg, Verweij, Krueger, Luciano, Arias Vasquez, Matteson, Derringer, Esko, Amin, Gordon, Hansell, Hart, Seppälä, Huffman, Konte, Lahti, Lee, Miller, Nutile, Tanaka, Teumer, Viktorin, Wedenoja, Abecasis, Adkins, Agrawal, Allik, Appel, Bigdeli, Busonero, Campbell, Costa, Davey Smith, Davies, de Wit, Ding, Engelhardt, Eriksson, Fedko, Ferrucci, Giegling, Gruzca, Hartmann, Heath, Heinonen, Henders, Homuth, Hottenga, Iacono, Janzing, Jokela, Karlsson, Kemp, Kirkpatrick, Latvala, Liewald, Madden, Magri, Magnusson, Marten, Medland, Mihailov, Milaneschi, Montgomery, Nauck, Ouwens, Palotie, Pettersson, Polasek, Qian, PulKKi-Råback, Realo, Rose, Ruggiero, Schmidt, Slutske, Sorice, St Pourcain, Sutin, Timpson, Trochet, Vermeulen, Vuoksimaa, Widen, Wouda, Wright, Zgaga, Porteous, Ouwens, Minelli, Palmer, Rujescu, Ciullo, Hayward, Rudan, Metspalu, Kaprio, Deary, Wilson, Keltikangas-Järvinen, Bierut, Hettema, Grabe, van Duijn, Evans, Schlessinger, Pedersen, Terracciano, McGue, Penninx, Martin, Boomsma.

Drafting of the manuscript: de Moor, van den Berg, Verweij, Luciano, Arias Vasquez, Esko, Konte, Lee, Henders, Lehtimäki, Maschio, Palotie, Minelli, Palmer, Grabe, Boomsma.

Critical revision of the manuscript for important intellectual content: de Moor, van den Berg, Verweij, Krueger, Arias Vasquez, Matteson, Derringer, Esko, Amin, Gordon, Hansell, Hart, Seppälä, Huffman, Lahti, Miller, Nutile, Tanaka, Teumer, Viktorin, Wedenoja, Abecasis, Adkins, Agrawal, Allik, Appel, Bigdeli, Busonero, Campbell, Costa, Davey Smith, Davies, de Wit, Ding, Engelhardt, Eriksson, Fedko, Ferrucci, Franke, Giegling, Gruzca, Hartmann, Heath, Heinonen, Homuth, Hottenga, Iacono, Janzing, Jokela, Karlsson, Kemp, Kirkpatrick, Latvala, Liewald, Madden, Magri, Magnusson, Marten, Medland, Mihailov, Milaneschi, Montgomery, Nauck, Ouwens, Palotie, Pettersson, Polasek, Qian, PulKKi-Råback, Raitakari, Realo, Rose, Ruggiero, Schmidt, Slutske, Sorice, Starr, St Pourcain, Sutin, Timpson, Trochet, Vermeulen, Vuoksimaa, Widen, Wouda, Wright, Zgaga, Porteous, Palmer, Rujescu, Ciullo, Hayward, Rudan, Metspalu, Kaprio, Deary, Råikkönen, Wilson, Keltikangas-Järvinen, Bierut, Hettema, Grabe, van Duijn, Evans, Schlessinger, Pedersen, Terracciano, McGue, Penninx, Martin.

Statistical analysis: de Moor, van den Berg, Verweij, Luciano, Arias Vasquez, Matteson, Derringer, Esko, Amin, Hansell, Hart, Seppälä, Huffman, Konte, Lahti, Lee, Miller, Nutile, Tanaka, Teumer, Viktorin, Wedenoja, Adkins, Allik, Bigdeli, Ding, Engelhardt, Fedko, Ferrucci, Jokela, Karlsson, Kemp, Magnusson, Marten, Medland, Mihailov, Milaneschi, Polasek, Qian, Ruggiero, Sorice, Wouda, Zgaga, Ciullo, Hayward, Hettema, Evans, Terracciano, McGue, Martin.

Obtained funding: de Moor, Abecasis, Campbell, Costa, Ferrucci, Franke, Giegling, Heath, Heinonen, Iacono, Lehtimäki, Madden, Montgomery, Polasek, PulKKi-Råback, Raitakari, Rose, Slutske, Starr, Wright, Porteous, Rujescu, Rudan, Kaprio, Deary, Råikkönen, Wilson, Grabe, van Duijn, Schlessinger, Pedersen, McGue, Penninx, Boomsma.

Administrative, technical, or material support: de Moor, van den Berg, Gordon, Hansell, Lahti, Abecasis, Adkins, Agrawal, Appel, Busonero, Campbell, Davey Smith, Davies, Eriksson, Giegling, Gruzca, Henders, Homuth, Hottenga, Jokela, Kirkpatrick, Lehtimäki, Madden, Magnusson, Maschio, Medland, Montgomery, Nauck, Ouwens, Polasek, PulKKi-Råback, Raitakari, Starr, Wright, Zgaga, Porteous, Palmer, Hayward, Kaprio, Deary, Keltikangas-Järvinen, Grabe, Pedersen, McGue.

Study supervision: de Moor, Arias Vasquez, Esko, de Wit, Ferrucci, Franke, Henders, Hottenga, Montgomery, Nauck, Palotie, Pettersson, PulKKi-Råback, Raitakari, Widen, Palmer, Rujescu, Ciullo, Rudan, Kaprio, Deary, Råikkönen, Grabe, van Duijn, McGue, Boomsma.

Conflict of Interest Disclosures: Dr Grabe reported having received funding by the German Research Foundation, the German Federal Ministry of Education and Research, and the DAMP Foundation as well as speaker's honoraria from Servier and Eli Lilly and Co. No other disclosures were reported.

Disclaimer: This publication is the work of the authors, and they will serve as guarantors for the contents of this article.

Additional Information: Analyses were carried out on the Genetic Cluster Computer (<http://www.geneticcluster.org>), which is supported by grant NWO 480-05-003 from the Netherlands Organization for Scientific Research. Generation Scotland is a collaboration between the University Medical Schools and the National Health Service (NHS), Aberdeen, Dundee, Edinburgh, and Glasgow, United Kingdom. Acknowledgments by the cohorts are listed in eAppendix 2 in the Supplement.

Additional Contributions: We thank all the participants.

REFERENCES

1. Fanous AH, Kendler KS. The genetic relationship of personality to major depression and schizophrenia. *Neurotox Res*. 2004;6(1):43-50.
2. Kotov R, Gamez W, Schmidt F, Watson D. Linking "big" personality traits to anxiety, depressive, and substance use disorders: a meta-analysis. *Psychol Bull*. 2010;136(5):768-821.
3. Distel MA, Trull TJ, Willemssen G, et al. The five-factor model of personality and borderline personality disorder: a genetic analysis of comorbidity. *Biol Psychiatry*. 2009;66(12):1131-1138.
4. Middeldorp CM, Cath DC, van den Berg M, Beem AL, Van Dyck R, Boomsma DI. The association of

personality with anxious and depressive psychopathology. In: Canli T, ed. *The Biological Basis of Personality and Individual Differences*. New York, NY: Guilford Press; 2006:251-272.

5. Xia J, He Q, Li Y, et al. The relationship between neuroticism, major depressive disorder and comorbid disorders in Chinese women. *J Affect Disord*. 2011;135(1-3):100-105.
6. Saulsman LM, Page AC. The five-factor model and personality disorder empirical literature: a meta-analytic review. *Clin Psychol Rev*. 2004;23(8):1055-1085.
7. Kendler KS, Myers J. The genetic and environmental relationship between major depression and the five-factor model of personality. *Psychol Med*. 2010;40(5):801-806.
8. Kendler KS, Myers J. The boundaries of the internalizing and externalizing genetic spectra in men and women. *Psychol Med*. 2014;44(3):647-655.
9. Ligthart L, Boomsma DI. Causes of comorbidity: pleiotropy or causality? shared genetic and environmental influences on migraine and neuroticism. *Twin Res Hum Genet*. 2012;15(2):158-165.
10. Terracciano A, Sutin AR, An Y, et al. Personality and risk of Alzheimer's disease: new data and meta-analysis. *Alzheimers Dement*. 2014;10(2):179-186.
11. Lahey BB. Public health significance of neuroticism. *Am Psychol*. 2009;64(4):241-256.
12. Watson D, Clark LA. On traits and temperament: general and specific factors of emotional experience and their relation to the five-factor model. *J Pers*. 1992;60(2):441-476.
13. De Fruyt F, Van De Wiele L, Van Heeringen C. Cloninger's psychobiological model of temperament and character and the five-factor model of personality. *Pers Individ Dif*. 2000;29(3):441-452. doi:10.1016/S0191-8869(99)00204-4.
14. Ferrando PJ. The measurement of neuroticism using MMQ, MPI, EPI and EPQ items: a psychometric analysis based on item response theory. *Pers Individ Dif*. 2001;30(4):641-656. doi:10.1016/S0191-8869(00)00062-3.
15. Church AT. Relating the Tellegen and five-factor models of personality structure. *J Pers Soc Psychol*. 1994;67(5):898-909.
16. Markon KE, Krueger RF, Watson D. Delineating the structure of normal and abnormal personality: an integrative hierarchical approach. *J Pers Soc Psychol*. 2005;88(1):139-157.
17. Costa PT, McCrae RR. *Professional Manual: Revised NEO Personality Inventory (NEO-PI-R) and NEO Five-Factor Inventory (NEO-FFI)*. Odessa, FL: Psychological Assessment Resources; 1992.
18. Eysenck HJ, Eysenck SBG. *Eysenck Personality Inventory*. San Diego, CA: Educational & Industrial Testing Service; 1964.
19. Eysenck HJ, Eysenck SBG. *Manual of the Eysenck Personality Questionnaire*. London, England: Hodder & Stoughton; 1975.
20. Eysenck SBG, Eysenck HJ, Barrett P. A revised version of the psychoticism scale. *Pers Individ Dif*. 1985;6(1):21-29. doi:10.1016/0191-8869(85)90026-1.

21. Cloninger CR. A systematic method for clinical description and classification of personality variants: a proposal. *Arch Gen Psychiatry*. 1987;44(6):573-588.
22. Cloninger CR, Svrakic DM, Przybeck TR. A psychobiological model of temperament and character. *Arch Gen Psychiatry*. 1993;50(12):975-990.
23. Patrick CJ, Curtin JJ, Tellegen A. Development and validation of a brief form of the Multidimensional Personality Questionnaire. *Psychol Assess*. 2002;14(2):150-163.
24. Tellegen A. *Manual of the Multidimensional Personality Questionnaire*. Minneapolis: University of Minnesota Press; 2000.
25. Bouchard TJ Jr, Loehlin JC. Genes, evolution, and personality. *Behav Genet*. 2001;31(3):243-273.
26. Yamagata S, Suzuki A, Ando J, et al. Is the genetic structure of human personality universal? a cross-cultural twin study from North America, Europe, and Asia. *J Pers Soc Psychol*. 2006;90(6):987-998.
27. Finkel D, McGue M. Sex differences and nonadditivity in heritability of the Multidimensional Personality Questionnaire Scales. *J Pers Soc Psychol*. 1997;72(4):929-938.
28. Keller MC, Coventry WL, Heath AC, Martin NG. Widespread evidence for non-additive genetic variation in Cloninger's and Eysenck's personality dimensions using a twin plus sibling design. *Behav Genet*. 2005;35(6):707-721.
29. Vink JM, Bartels M, van Beijsterveldt TCEM, et al. Sex differences in genetic architecture of complex phenotypes? *PLoS One*. 2012;7(12):e47371.
30. Lake RI, Eaves LJ, Maes HH, Heath AC, Martin NG. Further evidence against the environmental transmission of individual differences in neuroticism from a collaborative study of 45,850 twins and relatives on two continents. *Behav Genet*. 2000;30(3):223-233.
31. Wray NR, Birmaher BJ, Sullivan PF, Visscher PM, Martin NG. Genetic and phenotypic stability of measures of neuroticism over 22 years. *Twin Res Hum Genet*. 2007;10(5):695-702.
32. Fanous A, Gardner CO, Prescott CA, Cancro R, Kendler KS. Neuroticism, major depression and gender: a population-based twin study. *Psychol Med*. 2002;32(4):719-728.
33. Hettema JM, Neale MC, Myers JM, Prescott CA, Kendler KS. A population-based twin study of the relationship between neuroticism and internalizing disorders. *Am J Psychiatry*. 2006;163(5):857-864.
34. Kendler KS, Gatz M, Gardner CO, Pedersen NL. Personality and major depression: a Swedish longitudinal, population-based twin study. *Arch Gen Psychiatry*. 2006;63(10):1113-1120.
35. Boomsma DI, Beem AL, van den Berg M, et al. Netherlands twin family study of anxious depression (NETSAD). *Twin Res*. 2000;3(4):323-334.
36. van den Berg SM, de Moor MH, McGue M, et al. Harmonization of neuroticism and extraversion phenotypes across inventories and cohorts in the Genetics of Personality Consortium: an application of item response theory. *Behav Genet*. 2014;44(4):295-313.
37. Service SK, Verweij KJH, Lahti J, et al. A genome-wide meta-analysis of association studies of Cloninger's Temperament Scales. *Transl Psychiatry*. 2012;2:e116.
38. de Moor MH, Costa PT, Terracciano A, et al. Meta-analysis of genome-wide association studies for personality. *Mol Psychiatry*. 2012;17(3):337-349.
39. Wray NR, Pergadia ML, Blackwood DHR, et al. Genome-wide association study of major depressive disorder: new results, meta-analysis, and lessons learned. *Mol Psychiatry*. 2012;17(1):36-48.
40. Sullivan PF, de Geus EJC, Willemsen G, et al. Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. *Mol Psychiatry*. 2009;14(4):359-375.
41. Kohli MA, Lucae S, Saemann PG, et al. The neuronal transporter gene *SLC6A15* confers risk to major depression. *Neuron*. 2011;70(2):252-265.
42. Ripke S, Wray NR, Lewis CM, et al; Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium. A mega-analysis of genome-wide association studies for major depressive disorder. *Mol Psychiatry*. 2013;18(4):497-511.
43. Yang J, Benyamin B, McEvoy BP, et al. Common SNPs explain a large proportion of the heritability for human height. *Nat Genet*. 2010;42(7):565-569.
44. Vinkhuyzen AA, Pedersen NL, Yang J, et al. Common SNPs explain some of the variation in the personality dimensions of neuroticism and extraversion. *Transl Psychiatry*. 2012;2:e102.
45. Lubke GH, Hottenga JJ, Walters R, et al. Estimating the genetic variance of major depressive disorder due to all single nucleotide polymorphisms. *Biol Psychiatry*. 2012;72(8):707-709.
46. Verweij KJ, Yang J, Lahti J, et al. Maintenance of genetic variation in human personality: testing evolutionary models by estimating heritability due to common causal variants and investigating the effect of distant inbreeding. *Evolution*. 2012;66(10):3238-3251.
47. Benke KS, Nivard MG, Velders FP, et al; Early Genetics and Lifecourse Epidemiology Consortium. A genome-wide association meta-analysis of preschool internalizing problems. *J Am Acad Child Adolesc Psychiatry*. 2014;53(6):667-676.e7.
48. Visscher PM, Yang J, Goddard ME. A commentary on "common SNPs explain a large proportion of the heritability for human height" by Yang et al (2010). *Twin Res Hum Genet*. 2010;13(6):517-524.
49. Purcell SM, Wray NR, Stone JL, et al; International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature*. 2009;460(7256):748-752.
50. Ito H, Morishita R, Sudo K, et al. Biochemical and morphological characterization of MAGI-1 in neuronal tissue. *J Neurosci Res*. 2012;90(9):1776-1781.
51. Ito H, Morishita R, Iwamoto I, Mizuno M, Nagata K. MAGI-1 acts as a scaffolding molecule for NGF receptor-mediated signaling pathway. *Biochim Biophys Acta*. 2013;1833(10):2302-2310.
52. Karlsson R, Graae L, Lekman M, et al. *MAGI1* copy number variation in bipolar affective disorder and schizophrenia. *Biol Psychiatry*. 2012;71(10):922-930.
53. Ferentinos P, Rivera M, Ising M, et al. Investigating the genetic variation underlying episodicity in major depressive disorder: suggestive evidence for a bipolar contribution. *J Affect Disord*. 2014;155:81-89.
54. Etain B, Mathieu F, Rietschel M, et al. Genome-wide scan for genes involved in bipolar affective disorder in 70 European families ascertained through a bipolar type I early-onset proband: supportive evidence for linkage at 3p14. *Mol Psychiatry*. 2006;11(7):685-694.
55. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. *Lancet*. 2013;381(9875):1371-1379.
56. Middeldorp CM, de Moor MH, McGrath LM, et al. The genetic association between personality and major depression or bipolar disorder: a polygenic score analysis using genome-wide association data. *Transl Psychiatry*. 2011;1:e50.
57. Luciano M, Huffman JE, Arias-Vásquez A, et al. Genome-wide association uncovers shared genetic effects among personality traits and mood states. *Am J Med Genet B Neuropsychiatr Genet*. 2012;159B(6):684-695.
58. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. *Nature*. 2014;511(7510):421-427.
59. Wang K, Li M, Bucan M. Pathway-based approaches for analysis of genomewide association studies. *Am J Hum Genet*. 2007;81(6):1278-1283.
60. Montag C, Reuter M. Disentangling the molecular genetic basis of personality: from monoamines to neuropeptides. *Neurosci Biobehav Rev*. 2014;43:228-239.
61. Flint J. The genetic basis of neuroticism. *Neurosci Biobehav Rev*. 2004;28(3):307-316.
62. Nivard MG, Mbarek H, Hottenga JJ, et al. Further confirmation of the association between anxiety and *CTNND2*: replication in humans. *Genes Brain Behav*. 2014;13(2):195-201.
63. Sullivan PF. The Psychiatric GWAS Consortium: big science comes to psychiatry. *Neuron*. 2010;68(2):182-186.
64. Rietveld CA, Medland SE, Derringer J, et al; LifeLines Cohort Study. GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. *Science*. 2013;340(6139):1467-1471.
65. De Moor MHM, Boomsma DI, Stubbe JH, Willemsen G, de Geus EJC. Testing causality in the association between regular exercise and symptoms of anxiety and depression. *Arch Gen Psychiatry*. 2008;65(8):897-905.
66. Fanous AH, Neale MC, Aggen SH, Kendler KS. A longitudinal study of personality and major depression in a population-based sample of male twins. *Psychol Med*. 2007;37(8):1163-1172.
67. Visscher PM, Hemani G, Vinkhuyzen AA, et al. Statistical power to detect genetic (co)variance of complex traits using SNP data in unrelated samples. *PLoS Genet*. 2014;10(4):e1004269.